| Class | Non-depolarising NMJ blocker |
|---|---|
| Chemistry |
Benzylisoquinolinium diester |
| Routes of administration |
IV only |
| Absorption |
Poor absorption; minimal oral bioavailability |
| Solubility |
pKa=18.59; good water solubility |
| Distribution |
VOD= 0.15-0.34L/kg, 28% protein bound |
| Metabolism |
Metabolised by butyrylcholinesterase |
| Elimination |
Minimal renal or hepatic clearance |
| Time course of action |
Half lives of most isomers are short (2-5 minutes) |
| Target receptor |
Nicotinic acetylcholine receptors at the neuromuscular junction |
| Mechanism of action |
Nondepolarising neuromuscular junction blocker (competitive antagonist of acetylcholine); by binding to the nicotinic acetylcholine receptor, this agent blocks the binding of acetylcholine, and prevents the cation channel from opening, thus preventing the depolarisation of the motor endplate. |
| Clinical effects |
Nondepolarising neuromuscular junction blockade; |
| Literature reference |
Rubin et al (1995) |
| CICM details of understanding | Not specifically listed in the CICM syllabus |
| Mentioned around Deranged Physiology | |
| Related SAQs |